New research from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai identifies a protein that may be an unexplored target to develop new cancer therapies. The protein, known as kinase suppressor of Ras, or KSR, is a pseudoenzyme that plays a critical role in the transmission of signals in the cell determining whether cells grow, divide, or die. The findings, published in the September issue of the journal Nature, show that targeting KSR could have important therapeutic implications, potentially improving outcomes in many aggressing cancers such as lung and pancreatic cancer.
The lead compound reported in the study, APS-2-79, was shown to modulate Ras signaling and increased the potency of several other cancer drugs within RAS-mutant cell lines.
Read the complete news here.
Study mentioned:
Neil S. Dhawan, Alex P. Scopton, Arvin C. Dar. Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling. Nature, 2016; 537 (7618): 112 DOI: 10.1038/nature19327
No comments:
Post a Comment